A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder
Completed · Phase 1/Phase 2 · Has a placebo group
Conditions studied: Major Depressive Disorder
In brief
The purpose of this study is to determine the safety and tolerability of ascending oral doses of CYB003 in healthy participants with and without major depressive disorder (MDD).
Key facts
- Study ID
- NCT05385783
- Run by
- Cybin IRL Limited
- People needed
- 57
- Starts
- 2022-08-02
- Expected to finish
- 2024-01-18
- Last updated by the study team
- 2024-03-25
Who can join
Age: 21 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- CenExel ACMR — Atlanta, Georgia, United States
- iResearch Atlanta — Decatur, Georgia, United States
- Clinilabs Drug Development Corporation — Eatontown, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.